Cardinals manager Mike Shildt says COVID-19 outbreak has resulted in ‘a few visits’ to emergency room
Multiple Cardinals have experienced symptoms from the coronavirus
Related Articles
The Standard (S4, E8): Draft Ready | Pittsburgh Steelers
This episode features exclusive access with Omar Khan and Coach Tomlin at Pro Days, Pittsburgh native and scout Jim Ward, and a Kicking Clinic in…
Eli Lilly’s Zepbound eases obstructive sleep apnea in trials
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Eli Lilly’s Zepbound eases obstructive sleep apnea in trials
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Eli Lilly’s Zepbound eases obstructive sleep apnea in trials
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Eli Lilly’s Zepbound eases obstructive sleep apnea in trials
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH
A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, as the competition in the…
Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH
A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, as the competition in the…
The $100 billion club gets a shakeup, driven by biotech’s new blue-chip names
The drug industry officially has two new heavyweights. For the first time, Regeneron and Vertex have crossed the $100 billion market cap threshold. They join…
‘The Top Line’: Gene editing’s next act
Gene editing’s therapeutic application has transitioned from hypothetical to reality, marked by the recent approval of a CRISPR-based therapy for sickle cell and beta thalassemia. |…
Two GV partners on biotech’s reset and building their next drug startups
Newly named partner Anthony Philippakis and managing partner Krishna Yeshwant spoke with BioPharma Dive about biotech’s newfound optimism and their investing “North Star.”